Related Experiment Video
Updated: Jan 28, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
First-line PD-1 blockades combined with TKIs for metastatic non-clear cell renal cell carcinoma: a real-world
Xi Zhong1, Tingxuan Huang1, Yulu Peng1
1State Key Laboratory of Oncology in South China, Department of Urology Oncology, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Background:
Metastatic non-clear cell renal cell carcinoma (mnccRCC) are several rare subtypes of renal cell carcinoma, with standard treatment under investigation. This study retrospectively analyzes the largest Chinese cohort to assess the efficacy and safety of PD-1 blockades combined with tyrosine kinase inhibitors (TKIs) in mnccRCC.
Patients And Methods:
A retrospective review was conducted on treatment-naive patients with mnccRCC who received first-line PD-1 blockades combined with TKIs or TKIs monotherapy. The baseline characteristics of the patients and adverse events (AEs) were collected. Efficacy measures included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
Results:
The study enrolled 183 patients (99 TKI monotherapy, 84 combination therapy), with a median follow-up time of 20.0 (IQR, 11.1-32.4) months. ORR (32.1% vs. 20.2%) and DCR (82.1% vs. 55.6%) were improved in combination group compared with TKI group. Patients receiving combination therapy had a longer PFS and OS compared with those receiving TKI monotherapy [median PFS (95% CI): 19.1 (11.1-27.5) vs 8.1 (6.2-10.2)m, P < 0.001; median OS: not reached vs 44.1 (95% CI 27.4-70.0)m P = 0.017]. Subgroup analyses identified good performance status, non-chromophobe/Mit family translocation histologies and intermediate/poor IMDC classification derived pronounced survival advantages. The incidence of treatment-related AEs of grade three or higher was similar between the two groups (35.7% vs. 27.3%).
Conclusions:
PD-1 blockades combined with TKIs appeared an effective and safe choice in first-line treatment of mnccRCC, especially in individuals with good performance status, non-chromophobe/Mit family translocation histologies, and intermediate/poor IMDC classification.
Insights
Combining PD-1 blockades with tyrosine kinase inhibitors (TKIs) significantly improved outcomes for metastatic non-clear cell renal cell carcinoma (mnccRCC). This combination therapy demonstrated enhanced response rates and survival benefits compared to TKIs alone, with similar safety profiles.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Metastatic non-clear cell renal cell carcinoma (mnccRCC) comprises rare subtypes with limited standard treatment options.
- This study addresses the need for effective therapies in mnccRCC by investigating novel treatment combinations.
Purpose of the Study:
- To evaluate the efficacy and safety of combining PD-1 blockades with tyrosine kinase inhibitors (TKIs) as a first-line treatment for mnccRCC.
- To compare the outcomes of combination therapy versus TKI monotherapy in a large Chinese patient cohort.
Main Methods:
- Retrospective analysis of treatment-naive mnccRCC patients receiving first-line PD-1 blockade plus TKIs or TKIs monotherapy.
- Collected data on patient characteristics, adverse events, objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
Main Results:
- The combination group (84 patients) showed improved ORR (32.1% vs. 20.2%) and DCR (82.1% vs. 55.6%) compared to the TKI monotherapy group (99 patients).
- Combination therapy led to significantly longer PFS (19.1 vs. 8.1 months) and OS (not reached vs. 44.1 months).
- Similar rates of severe adverse events (grade 3+) were observed between groups (35.7% vs. 27.3%).
Conclusions:
- First-line PD-1 blockade combined with TKIs is an effective and safe treatment strategy for mnccRCC.
- Specific patient subgroups, including those with good performance status and certain histologies, benefit most from this combination therapy.
More Related Videos
Related Concept Videos
01:29Neuromuscular Junction And Blockade
01:24Serum Studies: Renal Function Tests
01:26PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
01:07Time-Domain Interpretation of PD Control
Consider the example of control of motor torque. Initially, a positive...
01:24Frequency-Domain Interpretation of PD Control
The proportional control gain, combined with the...
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...